Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

December 21, 2016

Conditions
Dysphonia Resulting From Vocal Fold ScarringAge-related Dysphonia
Interventions
BIOLOGICAL

Azficel-T (autologous fibroblasts)

"Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.~Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril."

DRUG

Placebo

Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).

Trial Locations (3)

10016

NYU Langone Medical Center, New York

90095

Surgery/Head and Neck, David Geffen School of Medicine at UCLA, Los Angeles

94305-5328

Dept of Otolaryngology, Stanford Univ Medical Center, Stanford

Sponsors
All Listed Sponsors
lead

Castle Creek Biosciences, LLC.

INDUSTRY